Human Intestinal Defensin 5 Inhibits SARS-CoV-2 Invasion by Cloaking ACE2

Inflammatory Bowel Disease

Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2 related disease

Gastroenterology

Suárez-Fariñas M, Tokuyama M, Wei G, Huang R, Livanos A, Jha D, Levescot A, Irizar H, Kosoy R, Cording S, Wang W, Losic B, Ungaro R, Di'Narzo A, Martinez-Delgado G, Suprun M, Corley MJ, Stojmirovic A, Houten SM, Peters L, Curran M, Brodmerkel C, Perrigoue J, Friedman JR, Hao K, Schadt EE, Zhu J, Ko HM, Cho J, Dubinsky MC, Sands BE, Ndhlovu L, Cerf-Bensusan N, Kasarskis A, Colombel JF, Harpaz N, Argmann C, Mehandru S

doi: 10.1053/j.gastro.2020.09.029

Inflammatory Bowel Disease

Age, inflammation and disease location are critical determinants of intestinal expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in inflammatory bowel disease

No abstract available

Hepatology

SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19

J Hepatol.

Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, Li X, Xu P, Zhang L, Zhao L, Cao Y, Kang J, Yang J, Li L, Liu X, Li Y, Nie R, Mu J, Lu F, Zhao S, Lu J, Zhao J

doi: 10.1016/j.jhep.2020.05.002.

Further Publications

Is SARS-CoV-2 Also an Enteric Pathogen with Potential Fecal-Oral Transmission: A COVID-19 Virological and Clinical Review

Gastroenterology.

Ding S, Liang TJ

doi: 10.1053/j.gastro.2020.04.052.

Further Publications

Detection of SARS-CoV-2 in Fecal Samples from Patients with Asymptomatic and Mild COVID-19 in Korea

Clin Gastroenterol Hepatol.

Park SK, Lee CW, Park DI, Woo HY, Cheong HS, Shin HC, Ahn K, Kwon MJ, Joo EJ

doi: 10.1016/j.cgh.2020.06.005.

Inflammatory Bowel Disease

Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD

Inflamm Bowel Dis.

Burgueño JF, Reich A, Hazime H, Quintero MA, Irina F, Fritsch J, Santander AM, Brito N, Damas OM, Deshpande A, Kerman DH, Zhang L, Gao Z, Ban Y, Wang L, Pignac-Kobinger J, Abreu MT

doi: 10.1093/ibd/izaa085.

Further Publications

Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection

Gut.

Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, Fang Z, Gu Z, Gao L, Shi H, Mai L, Liu Y, Lin X, Lai R, Yan Z, Li X, Shan H

doi: 10.1136/gutjnl-2020-321013.

Inflammatory Bowel Disease

Antibody Responses to SARS-CoV-2 After Infection or Vaccination in Children and Young Adults With Inflammatory Bowel Disease

Inflamm Bowel Dis

Dailey J, Kozhaya L, Dogan M, Hopkins D, Lapin B, Herbst K, Brimacombe M, Grandonico K, Karabacak F, Schreiber J, Liang BT, Salazar JC, Unutmaz D, Hyams JS

doi: 10.1093/ibd/izab207

Inflammatory Bowel Disease

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Gut

Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice R, Chee D, Cummings JF, Fraser A, Irving PM, Kamperidis N, Kok KB, Lamb CA, Macdonald J, Mehta S, Pollok RC, Raine T, Smith PJ, Verma AM, Jochum S, McDonald TJ, Sebastian S, Lees CW, Powell N, Ahmad T, Contributors to the CLARITY IBD study.

doi: 10.1136/gutjnl-2021-324789

Related content

Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2 related disease

Age, inflammation and disease location are critical determinants of intestinal expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in inflammatory bowel disease

SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19

Is SARS-CoV-2 Also an Enteric Pathogen with Potential Fecal-Oral Transmission: A COVID-19 Virological and Clinical Review

Detection of SARS-CoV-2 in Fecal Samples from Patients with Asymptomatic and Mild COVID-19 in Korea

Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD

Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection

Antibody Responses to SARS-CoV-2 After Infection or Vaccination in Children and Young Adults With Inflammatory Bowel Disease

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD